Home » Newsletters » BioWorld Science

BioWorld Science

March 19, 2007

View Archived Issues

NCX-4016 prevents endothelial dysfunction in intermittent claudication patients

HIV-specific T-cell responses seen with multiclade, multigene HIV vaccines

Anticancer compounds disclosed in recent patent literature

Recent patents disclose new therapeutic agents for sleep disorders and psychosis

Pegasys studied in difficult-to-treat hepatitis C patients

ZK-EPO reported highly effective in a breast cancer bone metastasis model

Ecopia BioSciences and Caprion complete business combination

Taribavirin studied in phase IIb trial for chronic hepatitis C

Novel TB vaccine shows promising immunogenicity in phase I trial

IMA-901 receives E.U. orphan drug status for renal cell cancer

Neose cleared to begin U.S. development of NE-180

Wyeth terminates SCOLR ibuprofen license

Abeille licenses AB-1001 emesis patch to SymBio for Japan and Pacific Rim countries

Vasostatin-Apo2L enters preclinical research

Trimeris regains rights to next-generation fusion inhibitors from Roche

Updated development status of Oxygent in China

Nippon Shinyaku and Teva terminate HMN-214 license agreement

Exelixis files IND for XL-147

Micromet grants Tracon rights to D93

Alkaline phosphatase shows benefit for patients with acute renal failure

Positive preclinical results of Colostrinin in mouse model of premature senescence

Losartan shows neuroprotection in a mouse model of Alzheimer's disease

First European launch for Dynepo

Soliris approved for paroxysmal nocturnal hemoglobinuria

GSK's novel BACE-1 inhibitor shows Abeta-lowering activity in vivo

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 4, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 4, 2025.
First phase of synthetic human genome project successfully completes
BioWorld
The first phase of the U.K. synthetic human genome project has successfully completed, realizing key steps in chromosome synthesis. The work has demonstrated a...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Laigo raises €11.5M seed money for targeted protein degradation
BioWorld Science
Laigo Bio BV has raised €11.5 million (US$13.7 million) in a seed round for the further development of a new approach to inducing targeted protein degradation by...